Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANZYGA Dose Regimens in Pediatric CIDP (Phase III)
2021-003200-40Phase 3
- Sponsor
- Octapharma
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Octapharma. Primary endpoint: CIDP improvement at Week 24.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2021-003200-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003200-40.